نتایج جستجو برای: melphalan

تعداد نتایج: 4419  

Journal: :Kidney & blood pressure research 2007
Romana Rysavá

Primary (AL amyloidosis) is a systemic disease characterized by an amyloid deposition process in many organs, with unsatisfactory survival of patients. The monoclonal light chains form the fibrils that deposit and accumulate in tissues. Renal involvement is very frequent in AL amyloidosis and could lead to development of nephrotic syndrome followed by the renal failure in many cases. Classic th...

Journal: :Anticancer research 2004
J Keenan Y Liang M Clynes

The accumulation of 2-deoxyglucose (2-DG), a glycolytic inhibitor, was investigated in a human nasal carcinoma cell line, RPMI-2650 and two of its drug-resistant variants (selected with taxol and melphalan) to assess manipulation of glycolytic potential as a selective means of reducing resistance. 2-DG uptake was increased 3-fold and 9.9-fold in taxol- and melphalan-resistant variants of RPMI-2...

Journal: :Blood 1978
R A Kyle P R Greipp

Satisfactory treatment for primary amyloidosis does not exist. Because the amyloid fibrils consist of a portion of a monoclonal light chain, it appears reasonable to treat amyloidosis with alkylating agents that are effective against the plasma cells that synthesize monoclonal light chains. Fifty-five patients with primary systemic amyloidosis were randomized (double blind) to melphalan-prednis...

Journal: :Journal of proteome research 2002
Yetrib Hathout Kelly Riordan Marion Gehrmann Catherine Fenselau

Analysis of differential protein expression in the cytosol of melphalan-resistant and -susceptible MCF-7 cell lines has been carried out using a combination of two-dimensional gel electrophoresis, mass spectrometry, and bioinformatics. Comparison of multiple digitized gel arrays detected several spots as candidates for differentially expressed proteins in melphalan-resistant MCF-7 cells. The up...

Journal: :Cancer research 1993
J Bramson J Prévost A Malapetsa A J Noë G G Poirier S DesNoyers M Alaoui-Jamali L Panasci

As a means of identifying damage recognition proteins involved in repair of nitrogen mustard lesions in chronic lymphocytic leukemia, we performed Southwestern analysis using a probe damaged with melphalan and protein extracts from chronic lymphocytic leukemia patients. We detected proteins with molecular weights of 116,000, 66,000, and 64,000 which bound the damaged probe with a higher specifi...

Journal: :Cancer research 1975
P N Rao S Mahagaokar E J Freireich T L Loo J A Gottlieb

The purpose of this study was to demonstrate that in vitro cell culture systems could serve a useful purpose in providing some guidelines in formulating drug schedules for combination cancer chemotherapy in the clinic. Using monolayer cultures of Chinese hamster ovary cells as the test system, we screened the combinations of 1-beta-D-arabinofuranosylcytosine (ara-C) + adriamycin, ara-C + 3,6 - ...

2017
Mette Marcussen Julie Støve Bødker Heidi Søgaard Christensen Preben Johansen Søren Nielsen Ilse Christiansen Olav Jonas Bergmann Martin Bøgsted Karen Dybkær Mogens Vyberg Hans Erik Johnsen

BACKGROUND Toxicity of the oral and gastrointestinal mucosa induced by high-dose melphalan is a clinical challenge with no documented prophylactic interventions or predictive tests. The aim of this study was to describe molecular changes in human oral mucosa and to identify biomarkers correlated with the grade of clinical mucositis. METHODS AND FINDINGS Ten patients with multiple myeloma (MM)...

Journal: :Annals of internal medicine 2004
Martha Skinner Vaishali Sanchorawala David C Seldin Laura M Dember Rodney H Falk John L Berk Jennifer J Anderson Carl O'Hara Kathleen T Finn Caryn A Libbey Janice Wiesman Karen Quillen Niall Swan Daniel G Wright

BACKGROUND AL amyloidosis is a fatal disease resulting from tissue deposition of amyloid fibrils derived from monoclonal immunoglobulin light chains. Treatment with oral chemotherapy is minimally effective. OBJECTIVE To test survival and organ response in a large sample of patients treated with high-dose intravenous melphalan (100 to 200 mg/m2) and autologous blood stem-cell transplantation. ...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2017
P Musto K C Anderson M Attal P G Richardson A Badros J Hou R Comenzo J Du B G M Durie J San Miguel H Einsele W M Chen L Garderet G Pietrantuono J Hillengass R A Kyle P Moreau J J Lahuerta O Landgren H Ludwig A Larocca A Mahindra M Cavo A Mazumder P L McCarthy A Nouel S V Rajkumar A Reiman E Riva O Sezer E Terpos I Turesson S Usmani B M Weiss A Palumbo

Background Therapeutic advancements following the introduction of autologous stem cell transplantation and 'novel' agents have significantly improved clinical outcomes for patients with multiple myeloma (MM). Increased life expectancy, however, has led to renewed concerns about the long-term risk of second primary malignancies (SPMs). This review outlines the most up-to-date knowledge of possib...

Journal: :Blood 1999
A Palumbo S Triolo C Argentino S Bringhen A Dominietto C Rus P Omedè C Tarella A Pileri M Boccadoro

A clinical relationship between dose-intensity of melphalan and response rate has been demonstrated in multiple myeloma. Promising results have been reported after 200 mg/m(2) melphalan, especially in younger patients. It is uncertain whether 100 mg/m(2) melphalan (MEL100) can offer similar results in older patients. To address this issue, patients were treated with 2 or 3 MEL100 courses follow...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید